Hubbell Incorporated to Appear at the Morgan Stanley Laguna Conference
Shelton, CT, Sept. 10, 2020 (GLOBE NEWSWIRE) — Hubbell Incorporated (NYSE: HUBB) today announced that Gerben Bakker, President and Chief Executive […]
Taat Engages Flinnwest to Deploy Investor Relations Strategies and Full-Scale Digital Media Initiatives for Beyond Tobacco™ Launch
With the launch of Beyond Tobacco™ cigarettes set to occur within the next 100 days, the Company has retained White […]
Golar LNG Partners LP: Class I Director Appointment
Golar LNG Partners LP: Class I Director AppointmentGolar LNG Partners L.P. (“Golar Partners”) announces today that its Board of Directors […]
CooperCompanies and Divisions Named One of Fortune’s Best Large Workplaces in Manufacturing and Production
SAN RAMON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO) announced today that the company, along with its […]
Myriad Genetics Expands Board of Directors with New Member
SALT LAKE CITY, Sept. 10, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global […]
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting
COPENHAGEN, Denmark, Sept. 10, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative […]
Nanox to Participate in Two Upcoming Investor Conferences
NEVE ILAN, Israel and TAIPEI, Taiwan, Sept. 10, 2020 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the […]
Freeline to participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully […]
Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for […]
Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage […]
